The generation of the so-called “radiosensitivity index” (RSI) forms a predictive signature of response to radiotherapy treatment composed of the AR, cJUN, STAT1, PKC, RELA, ABCc, SUMO1, CDK1, HDAC1, and IRF1 genes, which has been subsequently validated in cohorts of patients with breast cancer, head and neck cancer, esophageal cancer, rectal cancer, and glioblastoma multiforme [50,67,68]. This evidence concerns the gene IRF1 and esophageal cancer.